Moleculin Biotech Files 8-K
Ticker: MBRX · Form: 8-K · Filed: Nov 24, 2025 · CIK: 1659617
Sentiment: neutral
Topics: disclosure, filing
TL;DR
Moleculin Biotech filed an 8-K on Nov 24, 2025. Check for updates.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on November 24, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events beyond the filing itself are detailed in this excerpt.
Why It Matters
This filing indicates that Moleculin Biotech, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosure and exhibits, with no immediate indication of negative news or significant financial changes.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- November 24, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 47-4671997 (ein) — I.R.S. Employer Identification No.
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to provide Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is November 24, 2025.
What is the company's principal executive office address?
The company's principal executive office address is 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is Moleculin Biotech, Inc.'s state of incorporation?
Moleculin Biotech, Inc. is incorporated in Delaware.
What is the telephone number for Moleculin Biotech, Inc.?
The telephone number for Moleculin Biotech, Inc. is (713) 300-5160.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-11-24 09:08:12
Filing Documents
- mbrx20251121c_8k.htm (8-K) — 25KB
- ex_892003.htm (EX-99.1) — 25KB
- m01.jpg (GRAPHIC) — 5KB
- slide1.jpg (GRAPHIC) — 140KB
- slide2.jpg (GRAPHIC) — 144KB
- slide3.jpg (GRAPHIC) — 120KB
- slide4.jpg (GRAPHIC) — 118KB
- slide5.jpg (GRAPHIC) — 125KB
- slide6.jpg (GRAPHIC) — 126KB
- slide7.jpg (GRAPHIC) — 128KB
- slide8.jpg (GRAPHIC) — 131KB
- slide9.jpg (GRAPHIC) — 115KB
- slide10.jpg (GRAPHIC) — 102KB
- slide11.jpg (GRAPHIC) — 119KB
- slide12.jpg (GRAPHIC) — 160KB
- slide13.jpg (GRAPHIC) — 106KB
- slide14.jpg (GRAPHIC) — 120KB
- slide15.jpg (GRAPHIC) — 92KB
- slide16.jpg (GRAPHIC) — 119KB
- slide17.jpg (GRAPHIC) — 175KB
- slide18.jpg (GRAPHIC) — 108KB
- slide19.jpg (GRAPHIC) — 101KB
- slide20.jpg (GRAPHIC) — 107KB
- slide21.jpg (GRAPHIC) — 136KB
- slide22.jpg (GRAPHIC) — 161KB
- slide23.jpg (GRAPHIC) — 86KB
- slide24.jpg (GRAPHIC) — 104KB
- slide25.jpg (GRAPHIC) — 113KB
- slide26.jpg (GRAPHIC) — 111KB
- slide27.jpg (GRAPHIC) — 115KB
- slide28.jpg (GRAPHIC) — 136KB
- slide29.jpg (GRAPHIC) — 148KB
- slide30.jpg (GRAPHIC) — 112KB
- slide31.jpg (GRAPHIC) — 125KB
- slide32.jpg (GRAPHIC) — 113KB
- slide33.jpg (GRAPHIC) — 118KB
- slide34.jpg (GRAPHIC) — 113KB
- slide35.jpg (GRAPHIC) — 99KB
- slide36.jpg (GRAPHIC) — 116KB
- slide37.jpg (GRAPHIC) — 153KB
- slide38.jpg (GRAPHIC) — 111KB
- slide39.jpg (GRAPHIC) — 107KB
- slide40.jpg (GRAPHIC) — 86KB
- slide41.jpg (GRAPHIC) — 140KB
- slide42.jpg (GRAPHIC) — 105KB
- 0001437749-25-036082.txt ( ) — 7162KB
- mbrx-20251124.xsd (EX-101.SCH) — 3KB
- mbrx-20251124_def.xml (EX-101.DEF) — 12KB
- mbrx-20251124_lab.xml (EX-101.LAB) — 15KB
- mbrx-20251124_pre.xml (EX-101.PRE) — 12KB
- mbrx20251121c_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On November 24, 2025, Moleculin Biotech, Inc. (the "Company") is using the attached presentation for its corporate presentation posted on the Company's website and is set forth as Exhibit 99.1 herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Investor Presentation dated November 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: November 24, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster